modakafusp alfa + pomalidomide

**Modakafusp alfa + pomalidomide** is an investigational drug combination evaluated primarily in patients with relapsed/refractory multiple myeloma. Modakafusp alfa is a first-in-class immunocytokine engineered to deliver attenuated interferon alpha-2b specifically to CD38-expressing myeloma and immune cells, thereby inducing myeloma cell death and immune activation. Pomalidomide is an immunomodulatory agent (IMiD) that promotes anti-myeloma effects by acting on multiple cellular pathways including inhibition of angiogenesis (via VEGF and HIF-1\u03b1 reduction), direct anti-tumor actions (cell cycle arrest, apoptosis), and modulation of the tumor microenvironment. The combination aims to leverage the immune activation and direct antitumor properties of both drugs for the treatment of patients who have failed prior lines of therapy, particularly in relapsed or refractory states[1][2][4][5].

Other names

modakafusp alfa and pomalidomide